1. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961;2:1358.
2. Pannikar V. The return of thalidomide: new uses and renewed concerns. Lepr Rev 2003;74:286-288.
3. Waxman HA. The lessons of Vioxx: drug safety and sales. N Engl J Med 2005;352:2576-2578.
4. Baciu A, Stratton KR, Burke SP. Institute of Medicine (US), Committee on the Assessment of the US Drug Safety System. Institute of Medicine (US), Board on Population Health and Public Health Practice. The future of drug safety: promoting and protecting the health of the public 2006;Washington, DC: National Academies Press. 348.
5. Choi NK, Park BJ. Adverse drug reaction surveillance system in Korea. J Prev Med Public Health 2007;40:278-284.
6. Von Eschenbach AC. The FDA Amendments Act: reauthorization of the FDA. Food Drug Law J 2008;63:579-584.
7. The Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, 121 Stat. 823 (Sep 27, 2007), amending the Federal Food, Drug, and Cosmetic Act, 21 USC 301.
9. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel System: a national resource for evidence development. N Engl J Med 2011;364:498-499.
10. Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, Hennessy S, Nelson JC, Racoosin JA, Robb M, Schneeweiss S, Toh S, Weiner MG. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf 2012;21:Suppl 1. 1-8.
11. Wood SF, Perosino KL. Increasing transparency at the FDA: the impact of the FDA Amendments Act of 2007. Public Health Rep 2008;123:527-530.
12. Forrow S, Campion DM, Herrinton LJ, Nair VP, Robb MA, Wilson M, Platt R. The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program. Pharmacoepidemiol Drug Saf 2012;21:Suppl 1. 12-17.
14. Nguyen M, Ball R, Midthun K, Lieu TA. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiol Drug Saf 2012;21:Suppl 1. 291-297.
15. Fireman B, Toh S, Butler MG, Go AS, Joffe HV, Graham DJ, Nelson JC, Daniel GW, Selby JV. A protocol for active surveil-lance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent. Pharmacoepidemiol Drug Saf 2012;21:Suppl 1. 282-290.
16. Permanand G, Mossialos E, McKee M. Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance. Clin Med 2006;6:87-90.
17. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. What is ENCePP [Internet] cited 2012 Aug 16. London: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Available from:
http://www.encepp.eu/structure/index.html
19. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ENCePP studies [Internet] cited 2012 Aug 16. London: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Available from:
http://www.encepp.eu/encepp_studies/index.html